EquityZen Growth Technology Fund LLC - Series 292
Raised
$370K
Investors
20
Min Invest
$10,000
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 292 is a Delaware pooled investment vehicle filed by EquityZen Advisors on 2018-11-28, raising $370K from 20 investors under Rule 506(b) and Section 3(c)(1) exemptions. The fund requires a $10K minimum investment and is part of the EquityZen platform, which operates 1,891 related pre-IPO investment vehicles.
This pre-IPO pooled fund uses the standard 506(b)/3(c)(1) exemption structure common to private secondary market platforms, with a $10K minimum positioning it as accessible to accredited investors. The $18.5K average commitment and 20-investor structure are consistent with EquityZen's series-based approach to aggregating capital for secondary share purchases in private growth companies.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Richard Thoms
Executive Officer · Salt Lake City, UT
Assure Fund Management II LLC
Director · Salt Lake City, UT
Shriram Bhashyam
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.